MTD

As of 2026-10-26, MTD scores 55out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. MTD trades at $1669.62, 41% above the band ceiling.

MTD scores 55 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 55. Its strongest factor is momentum at 65 (solid), where price trend and relative strength are working in its favor, followed by volume at 61. The weakest is sentiment at 48, where sentiment signals are working against it. Among Healthcare stocks it ranks in roughly the top 27% of the Healthcare names the model scores.

On valuation, MTD is priced near the top of its recent range — the rich end on the model's valuation read. The five factors sit close together, so the composite reflects a balanced profile rather than one dominant driver. The blended composite before the macro overlay was 56. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on MTD, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where MTD sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for MTD runs $824.96–$1187.35. Current price $1669.62 sits 41% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.